Roflumilast is used for the treatment of frequent exacerbations or worsening symptoms of severe chronic obstructive pulmonary disease and improves symptoms, but is not indicated for the treatment of emphysema. Emphysema is an irreversible pathologic change that generally cannot be reversed by medication. Roflumilast is a selective type 4 phosphodiesterase inhibitor, clinically indicated for the treatment of cough and excessive mucus symptoms in severe COPD with bronchitis, and is not indicated for the treatment of emphysema and other types of COPD, and it should not be used to relieve acute bronchospasm. The most common adverse reactions to this product include nausea, diarrhea, insomnia, headache, back pain, decreased appetite, dizziness, etc. It is contraindicated for those who are allergic to this product, and those with moderate to severe hepatic insufficiency. Please use the medication according to the doctor’s prescription after the physician’s diagnosis, not blindly.